1443019-04-2

Upstream product

• 90843-31-5 1-(2,3-dihydrobenzofuran-5-yl)ethanone 
• 7149-10-2 vanillylamine hydrochloride 
• 130972-89-3 (4-hydroxy-3-methoxybenzyl)carbamic acid tert-butyl ester 
• 1443021-37-1 4-[2-(2,5-dioxo-pyrrolidin-1-yl)-ethoxy]-3-methoxy-benzaldehyde 
• 55943-72-1 N-(2-bromoethyl)-succinimide 
• 121-33-5 vanillin 
• 1443021-68-8 1-{2-[4-({[1-(2,3-dihydrobenzofuran-5-yl)ethyl]amino}methyl)-2-methoxyphenoxy]ethyl}pyrrolidine-2,5-dione 
• 99070-23-2 4-(2-bromo-ethoxy)-3-methoxy-benzaldehyde 

Downstream Products

• 1443019-12-2 trans-4-[([(R)-1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-1-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid 
• 1443019-16-6 trans-4-[([(S)-1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-1-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid 

Relevant academic research and scientific papers

I. Discovery of a novel series of CXCR3 antagonists. Multiparametric optimization of N,N-disubstituted benzylamines

N,N-Disubstituted benzylamine derivatives have been identified as CXCR3 antagonists. Compounds were optimized to improve affinity and selectivity, to increase metabolic stability in human and mouse liver microsomes, to increase Caco-2 permeability. Optimization was supported by monitoring physico-chemical properties using both experimental and computational means. Several compounds with double-digit nanomolar CXCR3 affinity, favorable selectivity, microsomal stability, Caco-2 permeability and human hepatocyte clearance have been identified.

CYCLOALKANE CARBOXYLIC ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula 1 that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to the novel intermediates used in the preparation of said compounds.

Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists

The present invention relates to compounds of formula 1 that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to the novel intermediates used in the preparation of said compounds.